These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3003649)

  • 1. The use of recombinant DNA technology for the development of a bluetongue virus subunit vaccine.
    Huismans H
    Onderstepoort J Vet Res; 1985 Sep; 52(3):149-51. PubMed ID: 3003649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response against the purified serotype specific antigen of bluetongue virus and initial attempts to clone the gene that codes for the synthesis of this protein.
    Huismans H; van der Walt NT; Erasmus BJ
    Prog Clin Biol Res; 1985; 178():347-53. PubMed ID: 2989871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potency and efficacy of inactivated bluetongue virus vaccines.
    Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
    Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a quadrivalent modified-live bluetongue virus vaccine in wildlife species.
    McConnell S; Morrill JC; Livingston CW
    Prog Clin Biol Res; 1985; 178():631-8. PubMed ID: 2989912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and serological response of sheep to serial challenge with different bluetongue virus types.
    Jeggo MH; Gumm ID; Taylor WP
    Res Vet Sci; 1983 Mar; 34(2):205-11. PubMed ID: 6304836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic response of sheep to inactivated and virulent bluetongue virus.
    Stott JL; Barber TL; Osburn BI
    Am J Vet Res; 1985 May; 46(5):1043-9. PubMed ID: 2988376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of neutralising antibody in passive immunity to bluetongue infection.
    Jeggo MH; Wardley RC; Taylor WP
    Res Vet Sci; 1984 Jan; 36(1):81-6. PubMed ID: 6324311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory evaluation of a living attenuated vaccine against bluetongue type 20 virus.
    Wark MC; Shepherd-Clark MB; Smith HV; Collins WD
    Aust Vet J; 1982 Jul; 59(1):6-10. PubMed ID: 6293439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
    Oura CA; Wood JL; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Floyd T; Simmons H; Batten CA
    Vaccine; 2009 Dec; 27(52):7326-30. PubMed ID: 19786141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current status of research on an experimental inactivated bluetongue virus vaccine.
    Stott JL; Osburn BI; Barber TL
    Proc Annu Meet U S Anim Health Assoc; 1979; (83):55-62. PubMed ID: 233389
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccines for bluetongue and other orbiviruses from a regulatory viewpoint.
    Strating A
    Prog Clin Biol Res; 1985; 178():627-9. PubMed ID: 2989911
    [No Abstract]   [Full Text] [Related]  

  • 12. An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy.
    Savini G; Ronchi GF; Leone A; Ciarelli A; Migliaccio P; Franchi P; Mercante MT; Pini A
    Vet Microbiol; 2007 Sep; 124(1-2):140-6. PubMed ID: 17499459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and serological outcome following the simultaneous inoculation of three bluetongue virus types into sheep.
    Jeggo MH; Wardley RC; Taylor WP
    Res Vet Sci; 1984 Nov; 37(3):368-70. PubMed ID: 6097969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental inactivated vaccine against bluetongue.
    Parker J; Herniman KA; Gibbs EP; Sellers RF
    Vet Rec; 1975 Mar; 96(13):284-7. PubMed ID: 165609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep.
    Eschbaumer M; Hoffmann B; König P; Teifke JP; Gethmann JM; Conraths FJ; Probst C; Mettenleiter TC; Beer M
    Vaccine; 2009 Jun; 27(31):4169-75. PubMed ID: 19406189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
    Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
    Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines.
    Bartram DJ; Heasman L; Batten CA; Oura CA; Plana-Durán J; Yuen HM; Wylie AD
    Vet J; 2011 May; 188(2):193-6. PubMed ID: 20466568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.
    Lobato ZI; Coupar BE; Gray CP; Lunt R; Andrew ME
    Vet Immunol Immunopathol; 1997 Nov; 59(3-4):293-309. PubMed ID: 9477479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bluetongue vaccine: cells and/or antibodies.
    Jeggo MH; Wardley RC
    Vaccine; 1985 Mar; 3(1):57-8. PubMed ID: 2988227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of bluetongue virus group-specific antigen VP3 in insect cells by a baculovirus vector: its use for the detection of bluetongue virus antibodies.
    Inumaru S; Ghiasi H; Roy P
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1627-35. PubMed ID: 3035063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.